Dynamic Modeling of the Angiogenic Switch and Its Inhibition by Bevacizumab
We formulate a dynamic model of vascular tumor growth, in which the interdependence of vascular dynamics with tumor volume is considered. The model describes the angiogenic switch; thus the inhibition of the vascularization process by antiangiogenic drugs may be taken into account explicitly. We val...
Saved in:
Main Authors: | Dávid Csercsik, Levente Kovács |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Complexity |
Online Access: | http://dx.doi.org/10.1155/2019/9079104 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evolution of uncontrolled proliferation and the angiogenic switch in cancer
by: John D. Nagy, et al.
Published: (2012-09-01) -
In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery
by: Yuanyuan Zhang, et al.
Published: (2019-01-01) -
Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
by: Zongyi Wang, et al.
Published: (2020-01-01) -
Inhibition of Angiogenic Factor Production from Murine Mast Cells by an Antiallergic Agent (Epinastine Hydrochloride) In Vitro
by: K. Asano, et al.
Published: (2008-01-01) -
Angiogenic Factors and Renal Disease in Pregnancy
by: Julie S. Rhee, et al.
Published: (2011-01-01)